Literature DB >> 17574305

Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology.

Marc Laburthe1, Alain Couvineau, Var Tan.   

Abstract

VIP and PACAP impact strongly on human pathophysiology. Their receptors are very promising targets for developing new drugs in the treatment of inflammatory and neurodegenerative diseases. This article reviews the present knowledge regarding VIP and PACAP receptors, i.e. VPAC1, VPAC2 and PAC1. This includes: (I) a critical review of instrumental peptide agonists and antagonists; (II) a survey of recent data regarding the structure of VPAC1 receptor and the docking of VIP in the receptor binding domain. Structural models for the VPAC2 and PAC1 receptor N-terminal ectodomains are also described; (III) A critical description of the two models of VPAC1 receptor activation in the general context of class II/family B G protein-coupled receptors.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17574305     DOI： 10.1016/j.peptides.2007.04.026

Source DB:  PubMed          Journal:  Peptides        ISSN： 0196-9781            Impact factor:   3.750


  63 in total

1.  Alternative splicing of the pituitary adenylate cyclase-activating polypetide (PACAP) receptor contributes to function of PACAP-27.

Authors:  Mina Ushiyama; Ryuji Ikeda; Morikatsu Yoshida; Kenji Mori; Kenji Kangawa; Hideki Sugawara; Kazuhiko Inoue; Katsushi Yamada; Atsuro Miyata
Journal:  J Mol Neurosci       Date:  2010-05-15       Impact factor: 3.444

Review 2.  VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins.

Authors:  Alain Couvineau; Marc Laburthe
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 3.  Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.

Authors:  Anthony J Harmar; Jan Fahrenkrug; Illana Gozes; Marc Laburthe; Victor May; Joseph R Pisegna; David Vaudry; Hubert Vaudry; James A Waschek; Sami I Said
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

4.  Changes in the expression of PACAP-like compounds during the embryonic development of the earthworm Eisenia fetida.

Authors:  Akos Boros; Dora Reglodi; Zsofia Herbert; Gabor Kiszler; Jozsef Nemeth; Andrea Lubics; Peter Kiss; Andrea Tamas; Seiji Shioda; Kouhei Matsuda; Edit Pollak; Laszló Molnar
Journal:  J Mol Neurosci       Date:  2008-07-08       Impact factor: 3.444

5.  PACAP receptor pharmacology and agonist bias: analysis in primary neurons and glia from the trigeminal ganglia and transfected cells.

Authors:  C S Walker; T Sundrum; D L Hay
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

6.  Pituitary adenylate cyclase-activating polypeptide is a potent broad-spectrum antimicrobial peptide: Structure-activity relationships.

Authors:  Charles G Starr; Jerome L Maderdrut; Jing He; David H Coy; William C Wimley
Journal:  Peptides       Date:  2018-04-11       Impact factor: 3.750

7.  VIP blockade leads to microcephaly in mice via disruption of Mcph1-Chk1 signaling.

Authors:  Sandrine Passemard; Vincent El Ghouzzi; Hala Nasser; Catherine Verney; Guilan Vodjdani; Adrien Lacaud; Sophie Lebon; Marc Laburthe; Patrick Robberecht; Jeannette Nardelli; Shyamala Mani; Alain Verloes; Pierre Gressens; Vincent Lelièvre
Journal:  J Clin Invest       Date:  2011-08       Impact factor: 14.808

Review 8.  Lifting the lid on GPCRs: the role of extracellular loops.

Authors:  M Wheatley; D Wootten; M T Conner; J Simms; R Kendrick; R T Logan; D R Poyner; J Barwell
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

9.  Protected graft copolymer excipient leads to a higher acute maximum tolerated dose and extends residence time of vasoactive intestinal Peptide significantly better than sterically stabilized micelles.

Authors:  Sandra Reichstetter; Gerardo M Castillo; Israel Rubinstein; Akiko Nishimoto-Ashfield; Manshun Lai; Cynthia C Jones; Aryamitra A Banerjee; Aryamitra Banjeree; Alex Lyubimov; Duane C Bloedow; Alexei Bogdanov; Elijah M Bolotin
Journal:  Pharm Res       Date:  2012-12-07       Impact factor: 4.200

10.  Curcumin in VIP-targeted sterically stabilized phospholipid nanomicelles: a novel therapeutic approach for breast cancer and breast cancer stem cells.

Authors:  Ece Gülçür; Mentor Thaqi; Fatima Khaja; Antonina Kuzmis; Hayat Önyüksel
Journal:  Drug Deliv Transl Res       Date:  2013-12       Impact factor: 4.617
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.